Can what have we learnt about BCG vaccination in the last 20 years help us to design a better tuberculosis vaccine?
Year: 2021
Type: article
Abstract: The BCG vaccine will, in 2021, have been in use for 100 years. Much remains to be understood, including the reasons for its variable efficacy against pulmonary tuberculosis in adults. This review will discuss what has been learnt about the BCG vaccine in the last two decades, and whether this new information can be exploited to improve its efficacy, by enhancing its ability to induce either antigen-specific and/or non-specific effects. Many factors affect both the immunogenicity of BCG and its protective efficacy, highlighting the challenges of working with a live vaccine in man, but new insights may enable us to exploit better what BCG can do.
Source: Vaccine
Authors: Hazel M. Dockrell, Egle Butkeviciute
Institution: London School of Hygiene & Tropical Medicine
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $2,950
Awards: G1043430953, G117390410, G127891921, TBVAC2020; Advancing novel and promising TB vaccine candidates from discovery to preclinical and early clinical development, VAccine deveLopment for complex Intracellular neglecteD pAThogEns (VALIDATE), DTP Bid Led by London Sch of Hygiene and Trop Medicine, G19746675, G2264598838, G2347075150, G4007824534, G434337789, G8028469421
OpenAlex ID: W3132862367